Citadel Advisors’s Eterna Therapeutics ERNA Stock Holding History

Citadel Advisors’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-23	Closed	-$42K	–	14985
2022 Q3	$42K	Sell	23 -1	-4%	-$3.45K	﹤0.01%	11743
2022 Q2	$92K	Buy	24 +10	+71%	+$71.8K	﹤0.01%	11491
2022 Q1	$223K	Buy	14 +11	+367%	+$209K	﹤0.01%	11262
2021 Q4	$93K	Sell	3 -6	-67%	-$326K	﹤0.01%	12789
2021 Q3	$642K	Sell	9 -1	-10%	-$86.3K	﹤0.01%	9275
2021 Q2	$1.33M	Buy	+10	New	+$1.44M	﹤0.01%	7605

Other funds holding ERNA

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's ERNA Position: Q1 2026 in Review

Citadel Advisors opened a new position in Eterna Therapeutics (ERNA) in Q1 2026: 1,323 shares worth $6.58K. The stake represents ﹤0.01% of the portfolio and ranks #12796 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ERNA as recently as Q1 2025.

Citadel Advisors first reported a position in ERNA in Q3 2018 and has held it in 13 quarters since. The position peaked at $490K in Q4 2021. 15 funds tracked by Wall St. Rank hold ERNA as of Q1 2026.

Citadel Advisors held 1,323 shares of Eterna Therapeutics worth $6.58K as of Q1 2026.
Eterna Therapeutics was a new Citadel Advisors position in Q1 2026.
Eterna Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12796 holding.
Citadel Advisors first reported a position in Eterna Therapeutics in Q3 2018 and has held it in 13 quarters since.
Citadel Advisors's Eterna Therapeutics position peaked at $490K in Q4 2021.
15 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.